Aignostics is an international, interdisciplinary team powering the next generation of precision medicine and advancing the fields of AI and pathology. Founded as a spin-off from Charité Berlin in 2020, the company builds on years of research conducted at Charité, TU Berlin, and Fraunhofer HHI. With offices in Berlin and New York, Aignostics offers a range of products and services geared towards precision medicine.

The mission of Aignostics is to transform drug development and improve patient outcomes using AI that delivers novel insights for precision medicine. Their proprietary access to multimodal data from over 30 million patients at leading university hospitals and laboratories enables this mission. The company boasts deep biomedical expertise with a team of data scientists, machine learning engineers, pathologists, and biologists providing expert input and oversight into all products and services.

Aignostics is recognized for its advanced machine learning capabilities, cutting-edge foundation models, and strong collaborations with academic partners in the EU and US. Their products and services support the evolving needs of precision medicine research.